● 公司2024年度财务报告被年审机构出具无法表示意见，触及财务类退市的情形，公司股票已被上海证 券交易所实施退市风险警示。具体内容详见公司于2025年4月30日披露的《关于实施退市风险警示及叠 加其他风险警示暨停牌的公告》（公告编号：临2025-032）。 ● 公司2024年度财务报告内部控制被年审机构出具无法表示意见；浙江复基控股集团有限公司的其他关 联方企业存在非经营性占用公司资金的情形。上述事项触及《上海证券交易所股票上市规则》第9.8.1条 第（一）（三）项的规定，公司被叠加实施其他风险警示。具体内容详见公司于2025年5月6日披露的 《关于控股股东关联方资金占用暨叠加其他风险警示的公告》（公告编号：临2025-034）。 登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要风险提示： ● 江苏吴中医药发展股份有限公司（以下简称"公司"）股票连续三个交易日内收盘价格涨幅偏离值累计 超过12%，属于股票交易异常波动的情形。 ● 公司股票近期涨幅较大，股价涨幅严重偏离基本 ...

Core Viewpoint - The stock of Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. has experienced abnormal trading fluctuations, with a cumulative closing price increase deviation exceeding 12% over three consecutive trading days, indicating potential market overheating and irrational speculation [1] Group 1: Stock Performance - The company's stock has seen a significant price increase, which is severely deviating from its fundamentals, suggesting a buildup of trading risks [1] - The abnormal trading behavior may lead to a rapid decline in stock price at any moment [1] Group 2: Risks - The company faces multiple delisting risks, including major legal violations, financial delisting, and par value delisting [1] - There are unresolved issues regarding the substantial fund occupation by the controlling shareholder, complete freezing of shares held by the controlling shareholder, and uncertainties surrounding the arbitration results of exclusive agency rights for medical beauty products [1]

Q&A 今年双十一的活动周期和核心销售时间节点有哪些变化？ 今年的双十一活动周期创下历史最长，抖音从 9 月中旬开始，持续约 57 天； 天猫预计从 10 月 9 日正式开始。整个周期分为五个阶段：预热期（9 月下旬至 10 月 19 日），主要进行领券和品牌预热种草；预售阶段（10 月 20 日至 30 日），美妆板块预计完成 45%左右的销售额；首轮爆发期（10 月 31 日至 11 月 10 日），各平台提供全品类优惠券和补贴；核心成交期（11 月 10 日至 11 日），预计占总成交额的 20%~30%；返场阶段可能延续 1~3 天。今年双十 一整体周期长达近 60 天。 今年双十一期间，各大平台对美妆品类的销售目标是什么？ 淘宝天猫平台内部预计 GMV 增长在 15%~20%左右，美妆品类希望达到 20%的增长。抖音全品类目标增长约 30%，美妆品类目标增长 35%~40%。 专家视角解读&双十一行情投资思路梳理 20250923 摘要 2025 年双十一周期长达近 60 天，淘宝天猫平台预计 GMV 增长 15%- 20%，美妆品类目标增长 20%；抖音全品类目标增长约 30%，美妆品 类目标增长 ...

Core Insights - The 25th China International Investment and Trade Fair (CITIF) held in Xiamen, Fujian, established a "Cross-Strait Integration Development Zone" to facilitate business opportunities for Taiwanese enterprises [1][2] - The fair featured over 120 delegations from various countries and regions, with a total exhibition area of 120,000 square meters and more than 100 investment promotion activities [1][3] - Taiwanese businesses expressed the importance of the fair as a platform for cross-strait economic exchanges and collaboration to explore overseas markets [1][3] Group 1: Event Highlights - The "Cross-Strait Integration Development Zone" showcased a variety of Taiwanese products, emphasizing the theme "New Integration, Connecting Two Sides, Creating the Future" with an area of 500 square meters [2] - Notable Taiwanese companies, such as Senita Cosmetics and Xiamen Dongya Machinery, presented innovative products and technologies, highlighting their commitment to collaboration and market expansion [2][3] - The fair serves as a critical bridge for Taiwanese businesses to integrate into the mainland market and modernize supply chains [5][6] Group 2: Economic Cooperation - Fujian has actively built a "Cross-Strait Integration Development Demonstration Zone," becoming a hub for cross-strait exchanges and economic cooperation, with the highest number of newly established Taiwanese enterprises in mainland China for three consecutive years [3][4] - The "Five Provinces and Cities Promotion Activity" aimed to enhance cooperation between Taiwanese businesses and mainland provinces, focusing on industry integration and leveraging regional advantages [4] - Taiwanese entrepreneurs expressed interest in collaborating with mainland industries, particularly in health and wellness sectors, to capitalize on the vast market opportunities [4][6] Group 3: Future Opportunities - The fair has become a significant platform for Taiwanese enterprises to seize new development opportunities and integrate into the mainland's industrial landscape [5][6] - Industry leaders emphasized the potential for collaboration in sectors such as artificial intelligence, biotechnology, and low-carbon industries, aiming to explore global market opportunities [6] - The event is viewed as a vital opportunity for Taiwanese businesses to connect with international resources and contribute to the modernization of the Chinese economy [6]

Core Insights - The 25th China International Investment and Trade Fair (CITIF) held in Xiamen, Fujian, established a "Cross-Strait Integration Development Zone" to facilitate business opportunities for Taiwanese enterprises [1][2] - The event featured over 120 delegations from various countries and regions, showcasing the importance of cross-strait economic and trade exchanges [1][3] Group 1: Event Highlights - The exhibition area covered 120,000 square meters, with more than 100 investment promotion activities conducted [1] - The "Cross-Strait Integration Development Zone" was themed "New Integration, Connecting Two Sides, Creating the Future," covering 500 square meters to display the achievements of cross-strait economic cooperation [2] - Taiwanese companies showcased innovative products, such as Morita's medical beauty products and Dongya Machinery's oil-free air compressors, emphasizing their technological advancements [2] Group 2: Economic Cooperation - Fujian has actively built a "Cross-Strait Integration Development Demonstration Zone," becoming a hub for cross-strait exchanges and economic cooperation [3] - The province has ranked first in the number of newly established Taiwanese enterprises and actual use of Taiwanese capital for three consecutive years [3] - The trade volume between Fujian and Taiwan is projected to grow by 4.2% in 2024, indicating a positive trend in cross-strait economic relations [3] Group 3: Business Opportunities - The "Five Provinces' Promotion of Business Environment to Taiwan" event facilitated project exchanges between Taiwanese businesses and five provinces, highlighting the potential for collaboration [4] - Taiwanese entrepreneurs expressed interest in leveraging the vast mainland market and unique regional resources for business growth [4] - The CITIF serves as a critical platform for Taiwanese enterprises to integrate into the mainland's industrial and supply chains, enhancing cross-strait economic exchanges [5][6]

*ST苏吴(600200.SH)发布风险提示公告，2025年7月13日，公司收到证监会下发的《行政处罚事先告知 书》，认定公司虚增营业收入、营业成本和利润，2020-2023年年度报告存在虚假记载，触及重大违法 强制退市情形。公司存在面值退市风险。公司股票收盘价已连续2个交易日低于人民币1元，如果连续20 个交易日的每日股票收盘价均低于1元，公司股票可能被上交所终止上市交易。公司目前存在控股股东 大额资金占用尚未解决、控股股东所持股份被全部冻结、医美产品独家代理解约并导致相关业务停滞等 多重风险，同时存在财务类退市、面值退市及重大违法强制退市等多重退市风险。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

Core Viewpoint - Four Seasons Pharmaceutical (00460) has seen a significant stock price increase, with a recent rise of over 8%, attributed to strong mid-year performance and strategic initiatives in AI technology for medical aesthetics [1] Financial Performance - The company reported a revenue of 1.15 billion HKD for the first half of the year, representing a year-on-year growth of 20.7% [1] - The overall gross margin improved to 66.1%, an increase of 2 percentage points compared to the previous year [1] - Research and development expenses decreased by 21.9% to 150 million HKD, a reduction of 43 million HKD year-on-year [1] - The company achieved a net profit of 66 million HKD, with a net profit attributable to shareholders of 103 million HKD, marking a turnaround from losses in the previous year [1] Strategic Initiatives - Four Seasons Pharmaceutical has signed a framework agreement with Deep Origin Pharmaceutical to promote the deep application and industrialization of AI technology in the development of medical aesthetic products [1] - The collaboration will lead to the establishment of an AI research and development company, indicating a significant step in the company's strategic layout in the "AI + Medical Aesthetics" innovation sector [1]

Group 1 - The core viewpoint of the article highlights the significant performance improvement of Four Seasons Pharmaceutical, with a notable increase in stock price and positive financial results [1] - The company reported a revenue of 1.15 billion yuan for the first half of the year, representing a year-on-year growth of 20.7% [1] - The overall gross margin improved to 66.1%, an increase of 2 percentage points compared to the previous year, driven by the high-margin medical aesthetics business [1] Group 2 - Research and development expenses decreased by 21.9% to 150 million yuan, a reduction of 43 million yuan year-on-year, indicating significant cost management improvements [1] - The company achieved a net profit of 66 million yuan, with a net profit attributable to shareholders of 103 million yuan, marking a turnaround from losses in the previous year [1] - Four Seasons Pharmaceutical announced a framework agreement with Deep Origin Pharmaceutical to establish an AI research and development company, focusing on the application of AI technology in the medical aesthetics sector [1]

Core Insights - Four Seasons Pharmaceutical (0460.HK) saw its stock price rise over 9.3% during trading, reaching a high of HKD 1.64, the highest since February 2022. The stock has increased over 140% year-to-date [1] Financial Performance - The company reported a mid-year revenue of CNY 1.146 billion, representing a year-on-year growth of 20.7% [1] - The net profit attributable to shareholders was CNY 103 million, marking a turnaround from losses in the previous year [1] - Overall gross margin improved to 66.1%, an increase of 2 percentage points year-on-year [1] - The medical aesthetics segment performed exceptionally well, generating revenue of CNY 590 million, a year-on-year increase of 81.3%, with segment profit reaching CNY 310 million, up 215.3% [1] - The company declared an interim cash dividend of CNY 0.0099 per share [1] Strategic Developments - Four Seasons Pharmaceutical has signed a framework agreement with Deep Origin Pharmaceutical Biotechnology (Beijing) Co., Ltd. to promote the application of artificial intelligence in the development of medical beauty products [1] - The partnership aims to establish an AI research and development company led by Four Seasons, focusing on exploring AI-driven new medical beauty product development, marking a significant step in the company's strategic layout in the AI + medical aesthetics innovation sector [1]

Core Viewpoint - *ST Suwu (600200.SH) has experienced significant stock price volatility, with a shift from a limit down to a limit up on September 2, indicating potential irrational speculation and multiple delisting risks [1] Financial Performance - The company reported a net loss attributable to shareholders of 44.42 million yuan for the first half of 2025, a decline of 281.63% compared to the same period last year [1] Regulatory Issues - On July 13, 2025, the company received an administrative penalty notice from the China Securities Regulatory Commission, which identified false records in revenue, costs, and profits in the annual reports from 2020 to 2023, triggering major illegal delisting scenarios [1] Operational Risks - The company faces multiple risks, including significant fund occupation by the controlling shareholder, complete freezing of shares held by the controlling shareholder, and the termination of exclusive agency agreements for medical beauty products, leading to business stagnation [1] Delisting Risks - The company is at risk of financial delisting, par value delisting, and major illegal delisting due to the aforementioned issues [1]